Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $16.45 USD
Change Today -0.55 / -3.24%
Volume 157.6K
DRNA On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

dicerna pharmaceuticals inc (DRNA) Snapshot

Open
$17.02
Previous Close
$17.00
Day High
$17.23
Day Low
$16.39
52 Week High
03/17/15 - $27.33
52 Week Low
11/6/14 - $8.00
Market Cap
338.5M
Average Volume 10 Days
345.7K
EPS TTM
$-2.88
Shares Outstanding
20.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DICERNA PHARMACEUTICALS INC (DRNA)

Related News

No related news articles were found.

dicerna pharmaceuticals inc (DRNA) Related Businessweek News

No Related Businessweek News Found

dicerna pharmaceuticals inc (DRNA) Details

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company’s development programs include DCR-PH1 for the treatment of primary hyperoxaluria type 1 (PH1) through targeting the gene encoding the liver enzyme glycolate oxidase; and other rare inherited diseases involving genes expressed in the liver. It is also developing DCR-MYC, which is in Phase I clinical study for the treatment of various cancers in patients with solid tumors, multiple myeloma, or lymphoma, as well as in Phase Ib/II clinical trial to treat cancer in patients with advanced hepatocellular carcinoma. In addition, the company is developing KRAS oncogene, a gene that is mutated in various cancers, including non-small cell lung cancer, colorectal cancer, and pancreatic cancer; and a therapeutic targeting a second cancer-related gene. It has a license agreement with City of Hope, an academic research and medical center to manufacture, use, offer for sale, sell, and import products related to DsiRNA for the prevention and treatment of various diseases in humans; licensing and collaboration agreement with Tekmira Pharmaceuticals Corporation to license LNP delivery technology for use in PH1 development program; and a license agreement with Plant Bioscience Limited to research, discover, develop, manufacture, sell, import, and export products incorporating short RNA molecules. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

42 Employees
Last Reported Date: 03/12/15
Founded in 2006

dicerna pharmaceuticals inc (DRNA) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $430.0K
Chief Financial Officer
Total Annual Compensation: $65.4K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $335.0K
Chief Medical Officer
Total Annual Compensation: $269.1K
Chief Business Officer
Total Annual Compensation: $295.0K
Compensation as of Fiscal Year 2014.

dicerna pharmaceuticals inc (DRNA) Key Developments

Dicerna Pharmaceuticals, Inc. Announces Expansion of Ongoing DCR-MYC Phase 1 Study to Evaluate Safety and Efficacy in Patients with Advanced Pancreatic Neuroendocrine Tumors

Dicerna Pharmaceuticals, Inc. announced it is expanding its ongoing Phase 1 study of DCR-MYC in solid tumors, multiple myeloma, or lymphoma to include a cohort of patients with pancreatic neuroendocrine tumors (PNETs) following early signs of clinical and metabolic response and tumor shrinkage in PNET patients. DCR-MYC is an investigational Dicer substrate short-interfering RNA (DsiRNA) therapeutic targeting the MYC oncogene and the first MYC-targeting short-interfering RNA (siRNA) to enter clinical trials. The ongoing Phase 1 study, initiated in April 2014, is a multi-center, dose-escalation trial designed to assess the safety and tolerability of DCR-MYC in patients with solid tumors, multiple myeloma, or lymphoma who are refractory or unresponsive to standard therapies. The study is designed to identify the maximum tolerated dose (MTD), the pharmacokinetic profile, potential pharmacodynamic effects, and antitumor activity of DCR-MYC. Once the MTD is established, an expansion cohort will be opened to enroll patients with PNET. This multi-center expansion cohort will enroll up to 20 patients with low- to intermediate-grade PNET who have demonstrated disease progression after treatment with standard therapies. Preliminary safety, tolerability, clinical, and metabolic response data from the ongoing Phase 1 trial of DCR-MYC will be presented at the 2015 ASCO Annual Meeting during the Tumor Biology Oral Abstract Session on June 1, 2015.

Dicerna to Present Interim Clinical Data from First DCR-MYC Phase 1 Study in Patients with Advanced Solid Tumors

Dicerna Pharmaceuticals, Inc. announced that new clinical data from a Phase 1 study of DCR-MYC in patients with solid tumors, multiple myeloma, or lymphoma. DCR-MYC is an investigational Dicer substrate short interfering RNA (DsiRNA) therapeutic targeting the MYC oncogene and the first MYC-targeting short interfering RNA (siRNA) to enter clinical trials. DCR-MYC is currently in two Phase 1 trials in patients with multiple tumor types. The abstract (#11006), titled Safety and activity of DCR-MYC, a first-in-class Dicer substrate small interfering RNA (DsiRNA) targeting MYC, in a phase 1 study in patients with advanced solid tumors [1], will be presented during the Tumor Biology oral abstract session on June 1, 2015 at 5:00 p.m. CDT by Anthony W. Tolcher, M.D., FRCP(C), of South Texas Accelerated Research Therapeutics (START).

Dicerna Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Dicerna Pharmaceuticals Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported loss from operations was $14,137,000 compared to $8,092,000 a year ago. Net loss attributable to common stockholders was $14,084,000 compared to $11,008,000 a year ago. Net loss per basic and diluted share allocable to common stockholders was $0.79 compared to $1.02 a year ago. Non-GAAP net loss per basic and diluted share allocable to common stockholders was $0.66 compared to $0.56 a year ago. Non-GAAP net loss was $11,764,000 compared to $6,033,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DRNA:US $16.45 USD -0.55

DRNA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DRNA.
View Industry Companies
 

Industry Analysis

DRNA

Industry Average

Valuation DRNA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DICERNA PHARMACEUTICALS INC, please visit www.dicerna.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.